766P - Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

Jens Voortman

766P - Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

Research output: Contribution to conference › Poster › Academic

Original language	English
Publication status	Published - 17 Sep 2020
Event	Euorpean Society for medical oncology : ESMO annual meeting 2020 - Duration: 14 Sep 2020 → …

Conference

Conference	Euorpean Society for medical oncology
Abbreviated title	ESMO
Period	14/09/2020 → …

Access to Document

Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274

Cite this

@conference{6d84c65ed54e448a9f5eafe312b55e7f,

title = "766P - Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study",

author = "Jens Voortman",

year = "2020",

month = sep,

day = "17",

language = "English",

note = "Euorpean Society for medical oncology : ESMO annual meeting 2020, ESMO ; Conference date: 14-09-2020",

}

TY - CONF

T1 - 766P - Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

AU - Voortman, Jens

PY - 2020/9/17

Y1 - 2020/9/17

UR - https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/prognostic-effect-of-systemic-immune-inflammation-index-sii-in-987-patients-with-advanced-metastatic-urinary-tract-carcinoma-mutc-treated-with

M3 - Poster

T2 - Euorpean Society for medical oncology

Y2 - 14 September 2020

ER -